Christina L Mikesell1,2, Robert R Kempainen3, Theresa A Laguna2, Jeremiah S Menk4, Andrew R Wey4, Philippe R Gaillard5, Warren E Regelmann6. 1. Children's Respiratory and Critical Care Specialists, Minneapolis, Minnesota. 2. Pediatric Pulmonology, University of Minnesota Cystic Fibrosis Center and Masonic Children's Hospital, Minneapolis, Minnesota. 3. Pulmonary and Critical Care Medicine, Hennepin County Medical Center, and the University of Minnesota Cystic Fibrosis Center and Hospital, Minneapolis, Minnesota. 4. Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota. 5. Department of Mathematics and Statistics, Auburn University, Auburn, Alabama. 6. Pediatric Pulmonology, University of Minnesota Cystic Fibrosis Center and Masonic Children's Hospital, Minneapolis, Minnesota. regel001@umn.edu.
Abstract
BACKGROUND: Objective measures of adherence to high-frequency chest wall compression (HFCWC), a form of airway clearance therapy for patients with cystic fibrosis, are lacking. We used a novel electronic monitoring device integrated into an HFCWC vest to measure adherence compared with self-reported adherence. We determined factors that influenced adherence and how adherence correlated with baseline pulmonary function and pulmonary exacerbations. METHODS: Data were collected by direct measurement of date, time of day, and duration of HFCWC use to determine the number of daily treatments and daily duration of treatments. Chart review provided prescribed airway clearance therapy treatment and demographic and clinical information. Subject and caregiver report of the daily number of airway clearance therapy treatments was obtained by telephone interviews. Analysis used 2-sample and paired t test, analysis of variance, and linear regression. RESULTS: Average adherence was 69%. Adherence was highest in children (82%, P = .02) and those receiving assistance with treatment (82%, P < .001). Subjects overestimated therapy duration from a mean ± SD of 127 ± 169% by adults to 19.2 ± 26.3% by parents or guardians of children. Average adherence decreased with increasing prescribed therapy time (P = .02). Average daily therapy time and adherence had significant positive associations with baseline FEV1 percent of predicted (P = .02 and P = .02, respectively) and negative associations with pulmonary exacerbations during the pre-study period and at baseline (P = .044 and P = .02, respectively). CONCLUSIONS: Greater adherence to HFCWC measured directly by a novel recorder was associated with better baseline pulmonary function and fewer exacerbations in the pre-study and baseline period. Adherence decreased with age and prescribed therapy time and increased with therapy assistance. Self-report overestimation is large and thus not an accurate measure of adherence.
BACKGROUND: Objective measures of adherence to high-frequency chest wall compression (HFCWC), a form of airway clearance therapy for patients with cystic fibrosis, are lacking. We used a novel electronic monitoring device integrated into an HFCWC vest to measure adherence compared with self-reported adherence. We determined factors that influenced adherence and how adherence correlated with baseline pulmonary function and pulmonary exacerbations. METHODS: Data were collected by direct measurement of date, time of day, and duration of HFCWC use to determine the number of daily treatments and daily duration of treatments. Chart review provided prescribed airway clearance therapy treatment and demographic and clinical information. Subject and caregiver report of the daily number of airway clearance therapy treatments was obtained by telephone interviews. Analysis used 2-sample and paired t test, analysis of variance, and linear regression. RESULTS: Average adherence was 69%. Adherence was highest in children (82%, P = .02) and those receiving assistance with treatment (82%, P < .001). Subjects overestimated therapy duration from a mean ± SD of 127 ± 169% by adults to 19.2 ± 26.3% by parents or guardians of children. Average adherence decreased with increasing prescribed therapy time (P = .02). Average daily therapy time and adherence had significant positive associations with baseline FEV1 percent of predicted (P = .02 and P = .02, respectively) and negative associations with pulmonary exacerbations during the pre-study period and at baseline (P = .044 and P = .02, respectively). CONCLUSIONS: Greater adherence to HFCWC measured directly by a novel recorder was associated with better baseline pulmonary function and fewer exacerbations in the pre-study and baseline period. Adherence decreased with age and prescribed therapy time and increased with therapy assistance. Self-report overestimation is large and thus not an accurate measure of adherence.
Authors: Gabriela R Oates; Irena Stepanikova; Steven M Rowe; Stephanie Gamble; Hector H Gutierrez; William T Harris Journal: Respir Care Date: 2018-12-11 Impact factor: 2.258
Authors: Emma Raywood; Helen Douglas; Kunal Kapoor; Nicole Filipow; Nicky Murray; Rachel O'Connor; Lee Stott; Greg Saul; Tim Kuzhagaliyev; Gwyneth Davies; Olga Liakhovich; Tempest Van Schaik; Bianca Furtuna; John Booth; Harriet Shannon; Mandy Bryon; Eleanor Main Journal: BMJ Open Date: 2020-10-07 Impact factor: 2.692